IN THE CLAIMS

Please amend the claims as follows:

Claim 1. (Currently Amended) A camptothecin analog having the structure:





where

X and Y are each independently ~~NO_2, NH_2, H, F, Cl, Br, I, COOH, OH, O-C_{1-6}-alkyl,~~ SH, S-C_{1-6} alkyl, ~~CN,~~ NH-C_{1-6} alkyl, ~~N(C_{1-6}-alkyl)$_2$,~~ CHO, ~~C_{1-8}-alkyl,~~ N_3,

-Z-$(CH_2)_a$-N-$((CH_2)_bOH)_2$, wherein Z is selected from the group consisting of O, NH and S, and a and b are each independently an integer of 2 or 3,

-Z-$(CH_2)_a$-N-(C_{1-6} alkyl)$_2$ wherein Z is selected from the group consisting of O, NH and S, and a is an integer of 2 or 3, or

-CH_2-L, where L is halogen (F, Cl, Br, I), $^+N_2$, $^+(OR^1)_2$, $^+S(R^1)_2$, $^+N(R^1)_3$, $OC(O)R^1$, OSO_2R^1, OSO_2CF_3, $OSO_2C_4F_9$, C_{1-6} alkyl-C(=O)-, C_{4-18} aryl-C(=O)-, C_{1-6} alkyl-SO_2-, perfluoro C_{1-6} alkyl-SO_2- or C_{4-18} aryl-SO_2-, (where each R^1 independently is C_{1-6} alkyl, C_{4-18} aryl or C_{4-18} ArC_{1-6} alkyl); ~~or~~

~~-$CH_2NR^2R^3$, where (a) R^2 and R^3 are, independently, hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, C_{2-6} alkenyl, hydroxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} COR^4 where R^4 is hydrogen, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, C_{2-6} alkenyl, hydroxyl C_{1-6} alkyl, C_{1-6} alkoxy, or C_{1-6} alkoxy C_{1-6} alkyl, or (b) R^2 and~~

~~R^3 taken together with the nitrogen atom to which they are attached form a saturated 3-7 membered heterocyclic ring which may contain a O, S or NR^5 group, where R^5 is hydrogen, C_{1-6} alkyl, perhalo C_{1-6} alkyl, aryl, aryl substituted with one or more groups selected from the group consisting of C_{1-6} alkyl, halogen, nitro, amino, C_{1-6} alkylamino, perhalo C_{1-6} alkyl, hydroxyl C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy C_{1-6} alkyl and $-COR^6$ where R^6 is hydrogen, C_{1-6} alkyl perhalo C_{1-6} alkyl, C_{1-6} alkoxy, aryl, and aryl substituted with one or more C_{1-6} alkyl, perhalo C_{1-6} alkyl, hydroxyl C_{1-6} alkyl, or C_{1-6} alkoxy C_{1-6} alkyl groups;~~

R^7 is ~~H, or $C(O)(CH_2)_m NR^8R^9$, where m is an integer of 1-6 or $-C(O)CHR^{10}NR^8R^9$, where R^{10} is the side chain of one of the naturally occurring α-amino acids, R^8 and R^9 are, independently, hydrogen, C_{1-8} alkyl or $-C(O)CHR^{11}NR^{12}R^{13}$ where R^{11} is the side chain of one of the naturally occurring α-amino acids and R^{12} and R^{13} are each independently hydrogen or C_{1-8} alkyl~~;

~~W is independently H or F,~~

R^{13} and R^{14} are each H or combine to form a double bond;

and

n is an integer of 1 or 2,

and salts thereof.

Claim 2. (Original) The camptothecin analog of claim 1, wherein n is 1.

Claim 3. (Original) The camptothecin analog of claim 1, wherein Y is $-CH_2$-L.

Claim 4. (Original) The camptothecin analog of claim 1, wherein L is selected from the group consisting of Cl, Br and I.

Claim 5. (Cancelled)

Claim 6. (Original) The camptothecin analog of claim 1, which is selected from the group consisting of R isomers, S isomers and mixtures thereof.

Claim 7. (Original) The camptothecin analog of claim 6, wherein the analog is the S isomer.

Claim 8. (Original) The camptothecin analog of claim 6, wherein the analog is the R isomer.

Claim 9. (Original) The camptothecin analog of claim 6, wherein the analog is an S rich mixture of S and R isomers.

Claim 10. (Original) The camptothecin analog of claim 6, wherein the analog is a R rich mixture of S and R isomers.

Claim 11. (Original) The camptothecin analog of claim 6, wherein the analog is a racemic mixture of R and S isomers.

Claim 12. (Original) A method of treating leukemia or solid tumors comprising administering to a patient in need thereof, the camptothecin analog of claim 1.

Claim 13. (Original) A pharmaceutical composition comprising the camptothecin analog of claim 1.

Claim 14. (Original) A method for inhibiting the enzyme topoisomerase I, comprising contacting a DNA-topoisomerase I complex with the camptothecin analog of claim 1.

Claim 15. (Currently Amended) A method of preparing the camptothecin analog according to claim 1 comprising:

condensing a compound of formula IV or V



(IV)



(V)

where X, Y, W and n are as defined in claim 1,

with a tricyclic ketone of formula III



(III)

where R^{13} and R^{14} are as defined in claim 1

to form the camptothecin analog of claim 1.

Claim 16. (New) A camptothecin analog having the structure:



(II)

where

X is NO_2, NH_2, H, F, Cl, Br, I, COOH, OH, O-C_{1-6} alkyl, SH, S-C_{1-6} alkyl, CN, NH-C_{1-6} alkyl, N(C_{1-6} alkyl)$_2$, CHO, C_{1-8} alkyl, N_3,

-Z-$(CH_2)_a$-N-$((CH_2)_bOH)_2$, wherein Z is selected from the group consisting of O, NH and S, and a and b are each independently an integer of 2 or 3,

-Z-$(CH_2)_a$-N-(C_{1-6} alkyl)$_2$ wherein Z is selected from the group consisting of O, NH and S, and a is an integer of 2 or 3,

-CH_2-L, where L is halogen (F, Cl, Br, I), $^+N_2$, $^+(OR^1)_2$, $^+S(R^1)_2$, $^+N(R^1)_3$, $OC(O)R^1$, OSO_2R^1, OSO_2CF_3, $OSO_2C_4F_9$, C_{1-6} alkyl-C(=O)-, C_{4-18} aryl-C(=O)-, C_{1-6} alkyl-SO_2-, perfluoro C_{1-6} alkyl-SO_2- or C_{4-18} aryl-SO_2-, (where each R^1 independently is C_{1-6} alkyl, C_{4-18} aryl or C_{4-18} ArC_{1-6} alkyl); or

-$CH_2NR^2R^3$, where (a) R^2 and R^3 are, independently, hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, C_{2-6} alkenyl, hydroxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} COR^4

where R^4 is hydrogen, C_{1-6} alkyl, perhalo C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl-C_{1-6} alkyl, C_{2-6} alkenyl, hydroxyl-C_{1-6} alkyl, C_{1-6}-alkoxy, or C_{1-6} alkoxy-C_{1-6} alkyl;

Y is SH, S-C_{1-6} alkyl, NH-C_{1-6} alkyl, -CHO, N_3,

-Z-$(CH_2)_a$-N-$((CH_2)_bOH)_2$, wherein Z is selected from the group consisting of O, NH and S, and a and b are each independently an integer of 2 or 3,

-Z-$(CH_2)_a$-N-$(C_{1-6}$ alkyl$)_2$ wherein Z is selected from the group consisting of O, NH and S, and a is an integer of 2 or 3, or

-CH_2-L, where L is halogen (F, Cl, Br, I), $^+N_2$, $^+(OR^1)_2$, $^+S(R^1)_2$, $^+N(R^1)_3$, $OC(O)R^1$, OSO_2R^1, OSO_2CF_3, $OSO_2C_4F_9$, C_{1-6} alkyl-C(=O)-, C_{4-18} aryl-C(=O)-, C_{1-6} alkyl-SO_2-, perfluoro C_{1-6} alkyl-SO_2- or C_{4-18} aryl-SO_2-, (where each R^1 independently is C_{1-6} alkyl, C_{4-18} aryl or C_{4-18} ArC_{1-6} alkyl);

R^7 is H;

R^{13} and R^{14} are each H or combine to form a double bond;

and

n is an integer of 1 or 2,

and salts thereof.

Claim 17. (New) A method of treating leukemia or solid tumors comprising administering to a patient in need thereof, the camptothecin analog of claim 16.

Claim 18. (New) A pharmaceutical composition comprising the camptothecin analog of claim 16.

Claim 19. (New) A method for inhibiting the enzyme topoisomerase I, comprising contacting a DNA-topoisomerase I complex with the camptothecin analog of claim 16.

Claim 20. (New) A method of preparing the camptothecin analog according to claim 16 comprising:

condensing a compound of formula IV or V



(IV)



(V)

where X, Y, W and n are as defined in claim 16,

with a tricyclic ketone of formula III



(III)

where R^{13} and R^{14} are as defined in claim 16

to form the camptothecin analog of claim 16.